Prof David Thomas, Director of the Kinghorn Cancer Centre, Founder of the Australian Cancer Genomics Medicine Programme, and arguably Australia’s leader in precision oncology, captivated attendees at the MPCCC’s March Precision Oncology Session with his presentation of the progress and potential of this field.

Prof Thomas revealed to stakeholders that “realising the potential of innovative personalised medicine for cancer patients” is a personal goal.  His research and clinical career, including innovative genomics research, clinical trials and the application of precision therapies for rare cancers and particularly Adolescents and Young Adult patients, inspired the formation of the Australian Cancer Genomics Medicine Programme, which is funded by the federal government.

Based in Sydney, the Australian Cancer Genomics Medicine Programme brings together over 80 organisations across Australia and internationally to provide a national diagnostics and research network, and to deliver a portal for pharmaceutical investment in Australia.

Prof Thomas concluded his presentation to over seventy MPCCC stakeholders at the Monash Health Translation Precinct by saying “This is a very exciting time to be involved in research”.

MPCCC’s Precision Oncology Seminar Program runs on a regular basis, and features profiled speakers with expertise and perspectives in Precision Oncology.

“This is a key forum to build our workforce, knowledge and expertise Precision Oncology”, said Prof Mark Shackleton, Leader of MPCCC’s Precision Oncology Program. “It will rotate across the MPCCC’s various partner sites and is open to anyone interested in helping our patients benefit from the application of Precision Oncology”, he said.